Skip to Content
Merck
  • Discovery of ligands for a novel target, the human telomerase RNA, based on flexible-target virtual screening and NMR.

Discovery of ligands for a novel target, the human telomerase RNA, based on flexible-target virtual screening and NMR.

Journal of medicinal chemistry (2008-10-28)
Irene Gómez Pinto, Christophe Guilbert, Nikolai B Ulyanov, Jay Stearns, Thomas L James
ABSTRACT

The human ribonucleoprotein telomerase is a validated anticancer drug target, and hTR-P2b is a part of the human telomerase RNA (hTR) essential for its activity. Interesting ligands that bind hTR-P2b were identified by iteratively using a tandem structure-based approach: docking of potential ligands from small databases to hTR-P2b via the program MORDOR, which permits flexibility in both ligand and target, with subsequent NMR screening of high-ranking compounds. A high percentage of the compounds tested experimentally were found via NMR to bind to the U-rich region of hTR-P2b; most have MW < 500 Da and are from different compound classes, and several possess a charge of 0 or +1. Of the 48 ligands identified, 24 exhibit a decided preference to bind hTR-P2b RNA rather than A-site rRNA and 10 do not bind A-site rRNA at all. Binding affinity was measured by monitoring RNA imino proton resonances for some of the compounds that showed hTR binding preference.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
4,4′-Dihydroxybenzophenone, 99%
SKU
Pack Size
Availability
Price
Quantity